News

Endpoints News18h
Ex­clu­sive: Car­diometa­bol­ic biotech gets $57.5M Se­ries B, with help from Cy­to­ki­net­ics
A biotech incubated by RA Capital has secured a $57.5 million Series B to begin a mid-stage trial for its cardio drug this ...